Özge Aynur, Ghouri Reza, Öksüz Nevra, Taşdelen Bahar
Department of Neurology, School of Medicine, Mersin University, Mersin, Türkiye.
Department of Biostatistics, School of Medicine, Mersin University, Mersin, Türkiye.
Front Neurol. 2023 Dec 13;14:1240655. doi: 10.3389/fneur.2023.1240655. eCollection 2023.
Dementia is a progressive neurodegenerative disorder characterized by cognitive decline, memory impairment, and functional deterioration. Pharmacological interventions play a crucial role in managing dementia symptoms and potentially slowing down disease progression.
This study aimed to investigate the impact of pharmacological interventions, including acetylcholinesterase inhibitors (AChEIs), memantine, and extract, on the progression of dementia, with a specific focus on mild cognitive impairment (MCI), Alzheimer's disease (AD), and non-Alzheimer dementias.
A total of 547 participants out of 3,547 cases in a specific dataset followed by the same author, including healthy controls, individuals with MCI, AD, and non-Alzheimer dementias, were included in this study. The follow-up duration was up to 211 months, allowing for a minimum 3 visits comprehensive assessment of disease progression. The treatment approaches included AChEIs, memantine, and combination therapy, with variations in the starting time for these treatments based on the dementia type.
The use of AChEIs and memantine showed efficacy in improving cognitive function and overall function in individuals with MCI, AD, and non-AD dementias. Combination therapy EGb761 like extract with AChEIs and/or Memantine demonstrated a slower progression compared to AChEIs alone in individuals with prodromal dementia (MCI) and AD. The starting time for memantine and combination therapy was earlier in non-AD dementia cases compared to AD dementia cases and prodromal dementia.
Pharmacological interventions, particularly the use of AChEIs and memantine, can have a positive impact on cognitive function and overall function in individuals with dementia. The combination of AChEIs with EGb761 like extract may provide additional benefits in slowing down disease progression in AD cases. Early recognition and accurate classification of MCI subtypes are crucial, and the use of EGb761 like extract is recommended for symptomatic treatment. Future personalized risk predictions based on biomarker constellations may further enhance the multi-target treatment approaches of MCI and different dementia types.
痴呆是一种进行性神经退行性疾病，其特征为认知能力下降、记忆障碍和功能衰退。药物干预在控制痴呆症状以及可能减缓疾病进展方面起着关键作用。
本研究旨在调查包括乙酰胆碱酯酶抑制剂（AChEIs）、美金刚和[提取物名称]提取物在内的药物干预对痴呆进展的影响，特别关注轻度认知障碍（MCI）、阿尔茨海默病（AD）和非阿尔茨海默痴呆。
在同一作者跟踪的特定数据集中的3547例病例中，共有547名参与者被纳入本研究，包括健康对照、MCI患者、AD患者和非阿尔茨海默痴呆患者。随访时间长达211个月，允许进行至少3次疾病进展的综合评估。治疗方法包括AChEIs、美金刚和联合治疗，这些治疗的起始时间根据痴呆类型有所不同。
使用AChEIs和美金刚在改善MCI、AD和非AD痴呆患者的认知功能和整体功能方面显示出疗效。在前驱性痴呆（MCI）和AD患者中，与单独使用AChEIs相比，联合治疗（如EGb761[提取物名称]提取物与AChEIs和/或美金刚）显示疾病进展较慢。与AD痴呆病例和前驱性痴呆相比，美金刚和联合治疗在非AD痴呆病例中的起始时间更早。
药物干预，特别是使用AChEIs和美金刚，可对痴呆患者的认知功能和整体功能产生积极影响。AChEIs与EGb761[提取物名称]提取物联合使用可能在减缓AD病例的疾病进展方面提供额外益处。早期识别和准确分类MCI亚型至关重要，建议使用EGb761[提取物名称]提取物进行对症治疗。基于生物标志物组合的未来个性化风险预测可能会进一步加强MCI和不同痴呆类型的多靶点治疗方法。
